Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $IMGN Video Chart 11-05-2019 * *
Link to Video - click here to watch the technical chart video
News: $IMGN Why ImmunoGen Stock Is Crushing It Today
Shares of ImmunoGen (NASDAQ: IMGN) were soaring 14.8% higher as of 11:20 a.m. EST on Tuesday. The biotech provided its third-quarter update last Friday. While its financial results were nothing to get excited about, investors cheered its progress with a late-stage clinical study evaluating...
In case you are interested IMGN - Why ImmunoGen Stock Is Crushing It Today
* * $IMGN Video Chart 11-01-2019 * *
Link to Video - click here to watch the technical chart video
I believe the 4 presentation they're making at ASH on IMGN632 will spur additional interest in the stock, and hopefully we'll end the year much closer to the high, rather than the lows where we're currently languishing.
As someone in remission after stem cells for ALL I'm happy to hear they're now working with it. I don't believe they're going after the specific form I have, but I know that much off label use is made, so no telling if it could be effective. I'm approaching 5 years post stem cells, but remain on chemo as it greatly diminishes the likelihood of coming out of remission. I hope not to ever need anything more, but it would still nice to know it exists if I do.
Gary
News: $IMGN ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End Updated IMGN632 AML and BPDCN Monotherapy Data Accepted as Oral Presentation at A...
Read the whole news IMGN - ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
* * $IMGN Video Chart 10-21-2019 * *
Link to Video - click here to watch the technical chart video
* * $IMGN Video Chart 09-30-2019 * *
Link to Video - click here to watch the technical chart video
It seems like investors don't like what IMGN said, even though it's essentially what they've been saying all along. A new trial will be started this year that could have IMGN853 approve by about 2022.
I'll admit, their presentation put me to sleep, so I cannot speak to every word, but I believe they've learned much from the failed trial, and the patients in the new trial will be better qualified to receive the maximum benefits. In the failed trial there are certainly a number of patients who're still alive who wouldn't have expected to be with the SOC, but that's not the acceptance criteria. It's sad, investigators can clearly see a certain group that benefits, yet the regulators can't see it being definitive enough to approve the drug with a limited label.
Gary
Let's see what's said tomorrow when they're speaking to investors. Hopefully they'll reveal when the new Phase 3 will be initiated, and we'll get further information on their other plans as well.
To all my fellow Jewish investors, L'Shanah Tova.
Gary
I totally agree
Next week is looking good!
09/20/19 16:00:37 3.31 3.27 3.35 200
09/20/19 16:00:36 3.31 3.25 3.35 238
09/20/19 16:00:35 3.31 3.25 3.35 635
09/20/19 16:00:23 3.31 3.25 3.35 739,189
09/20/19 16:00:17 3.34 3.25 3.35 5,446
09/20/19 16:00:00 3.335 3.30 3.31 4,102,635
09/20/19 15:59:58 3.34 3.30 3.31 170
09/20/19 15:59:57 3.34 3.30 3.31 200
09/20/19 15:59:56 3.34 3.30 3.31 390
09/20/19 15:59:55 3.34 3.30 3.31 1,737
09/20/19 15:59:54 3.34 3.30 3.31 16,764
09/20/19 15:59:52 3.34 3.32 3.33 200
09/20/19 15:59:51 3.34 3.32 3.33 452
09/20/19 15:59:51 3.34 3.33 3.34 18,197
09/20/19 15:59:50 3.34 3.33 3.34 781
09/20/19 15:59:49 3.34 3.33 3.34 2,300
09/20/19 16:00:23 3.31 3.25 3.35 739,189
09/20/19 16:00:00 3.335 3.30 3.31 4,102,635
08/28/19 16:00:04 2.59 2.56 2.62 507,800
08/28/19 16:00:00 2.59 2.59 2.60 552,263
08/19/19 16:17:00 2.85 2.83 2.86 700,000
08/12/19 16:00:12 2.83 2.80 2.87 758,200
07/22/19 16:00:00 2.29 2.27 2.30 816,900
07/22/19 16:00:00 2.29 2.28 2.29 813,299
07/18/19 17:36:55 2.31 2.26 2.31 1,169,900
07/18/19 16:16:49 2.31 2.26 2.31 1,832,300
07/17/19 17:09:42 2.27 2.24 2.32 1,020,100
07/12/19 16:00:00 2.43 2.43 2.45 544,862
Could be the ESMO presentations, here's a link to a post with the schedule:
https://www.investorvillage.com/smbd.asp?mb=1316&mn=49836&pt=msg&mid=19778711
Gary
There should be substantial news between now and the end of the year with presentations expected at ESMO and ASH, but I suspect behind the scenes partnerships may be in discussions, but no telling if or when they'll come to fruition.
Gary
* * $IMGN Video Chart 08-06-2019 * *
Link to Video - click here to watch the technical chart video
News: $IMGN Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential
August 6, 2019 Palm Beach, FL –August 6, 2019 – According to an industry report , the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from 2018 to 2025....
Read the whole news Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential
* * $IMGN Video Chart 08-05-2019 * *
Link to Video - click here to watch the technical chart video
I believe the S-A article on IMGN is presenting what's happening well.
https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?app=1
Gary
I believe the S-A article on IMGN is presenting what's happening well.
https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?app=1
Gary
I view it as a positive that investors advised against the executive incentives. A few years ago it was tied to share price improvement, and I'm fine with that, but rewards for being at many years lows makes little sense. I don't believe we'll be down here forever, I'm hoping for new highs, at that time, ask us again.
Gary
* * $IMGN Video Chart 06-21-2019 * *
Link to Video - click here to watch the technical chart video
Tomorrow is IMGN's Annual Meeting. I don't know if anything major will be announced there, but I certainly hope further guidance will be provided on how they're proceeding with IMGN853, and perhaps if under confidentiality agreements discussions are underway for a ROW partnership for the drug which previously had been discussed by the company. I'm uncertain if IMGN wants all of North America for itself, or just the U.S., but it's been clear that the ROW is open to a partnership.
I believe that IMGN is dramatically undervalued and as more information is released on a few different products that they, and their partners are working on, the price will rise to at least low double digits by the end of the year, or early next year. That said, I found the January $4 calls to attractive to pass up. If I'm right, I'll sell a small fraction of what I've bought to pay for purchasing all the rest as I've promised my wife I wouldn't use more cash to purchase more IMGN.
Gary
I agree to a degree, but a ROW partnership for IMGN853 would answer all the questions, and the time is right for it. That partner could potentially gain European approval without further trial. IMGN would easily be in double digits.
On a personal note, I've just had 2 surgeries in under 6 days, so I'm slightly out of it.
Gary
A good overview of what is going on with IMGN:
I believe this is changing:
You may very well be right, but even the Institutions need something positive to build the price when they push to do so. I believe the Phase 3 data clearly indicated that with the proper target the drug will easily be approved. I'm hoping a partnership well before that time will answer all questions about future funding, and drugs beyond IMGN853 will also be nearing approval.
This company still has the potential of exceeding SGEN's market cap, but it needs one or more of it's own drugs to be approved. While European approval is still a possibility, the FDA remains the gold standard, and clearly that will be a few years.
Gary
Institutional interest is around 75%. I believe that the biggest reason for this battering is they want retail OUT of IMGN.
I believe the EU and the rest of the world are becoming more data driven i their approvals. Also risk/reward is an issue when they believe a drug does not increase risk but can save lives and healthcare system dollars.
Unfortunately saved lives and quality of life are less important in our pay for play system.
In the IMGN conference call yesterday they indicated that later this year they'll approach the European authorities to discuss the potential of approval there based on the Phase 3 Trial. In that IMGN has always indicated an intent to do a ROW partnership and not market outside of North America, or possibly just the U.S. themselves, it would make sense for them to make that partnership with BP before approaching the European authorities.
At this point they know what the drug does, they know it can obtain approvals in the right platinum resistant group, and it still may be expanded to other cancers with similar platinum resistance. A potential partner certainly won't pay as much as they would have had the Phase 3 Trial been successful, but they still should be willing to pay substantially for a drug that should be approved in the U.S. and a few years, and could possibly be approved where they'll have the rights much sooner.
I'm not saying this will happen, but it's a strategy that would assure IMGN the funds needed for all the trials it has underway without massive dilution, and it would have the European authorities, and others, working with a BP who already has a presents in their country.
Gary
Two reasons, options expiration and they want to shake out the margin call shares.
Why is IMGN trading down today? The morning PR yesterday may be one reason, but the 5:01 PR yesterday should have tempered the morning PR. The evening PR looks encouraging to me;where am I wrong?:
http://ih.advfn.com/stock-market/NASDAQ/immunogen-IMGN/stock-news/79925967/immunogen-announces-mature-data-from-forward-ii-ex
"ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin...
Results to be Presented at 2019 ASCO Annual Meeting
Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease
Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with folate receptor alpha (FRa)-positive platinum-resistant ovarian cancer. These findings will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31 – June 4 in Chicago, IL.
“We are pleased that the combination of mirvetuximab plus Avastin has generated significant anti-tumor activity in patients with platinum-resistant disease, with trends toward deeper, more durable responses seen in individuals with higher FRa expression and a favorable tolerability profile. The outcomes observed in patients with medium or high FRa expression are encouraging with respect to those reported in similar patient populations for Avastin plus chemotherapy,” said Anna Berkenblit, M.D., Vice President and Chief Medical Officer of ImmunoGen. “Our goal remains to establish mirvetuximab as the combination agent of choice in ovarian cancer, supporting its use in earlier lines of therapy. These mature data support further exploration of this doublet, as well as the ongoing expansion study evaluating a triplet combination of mirvetuximab with Avastin and carboplatin in patients with platinum-sensitive disease.”
DATA FROM FORWARD II EXPANSION COHORT WITH AVASTIN
Mirvetuximab soravtansine in combination with Avastin in patients with FRa-positive platinum-resistant ovarian cancer continues to demonstrate anti-tumor activity with durable responses and a favorable tolerability profile, particularly among the subset of patients who have received up to two prior lines of therapy and have medium or high levels of FRa expression.
Key findings in 66 patients with platinum-resistant disease include:
In the subset of 16 Avastin-naïve patients with medium or high FRa expression who have received up to two prior lines of therapy, the confirmed overall response rate (ORR) was 56 percent (95% CI 30,80), with a median progression-free survival (PFS) of 9.9 months (95% CI 4.1,15.9) and a median duration of response (DOR) of 12 months (95% CI 6,14.9).
In the overall patient population, the confirmed ORR was 39 percent (95% CI 28,52), with a median PFS of 6.9 months (95% CI 4.9,8.6) and a median DOR of 8.6 months (95% CI 4.9, 14.9).
The combination continues to display a safety profile in-line with the known profiles of each agent, with no new safety signals identified.
“Current treatment options for patients with platinum-resistant ovarian cancer have, unfortunately, exhibited limited efficacy with challenging side effects,” stated David O'Malley, M.D., Professor, Director of Gynecology Clinical Trials and Phase 1 Program, James Cancer Center and The Ohio State University Wexner Medical Center, and FORWARD II Principal Investigator. “Final results from the combination of mirvetuximab soravtansine and Avastin expansion cohort demonstrate very encouraging activity and good tolerability in platinum-resistant ovarian cancer patients, especially those with medium or high FRa expression levels. I look forward to further evaluating mirvetuximab in combination with Avastin as well as in the triplet with carboplatin.”
ASCO PRESENTATION DETAILS
Title: “Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study”
Day/Time: Saturday, June 1, 1:15pm - 4:15pm CDT and discussed at the Poster Discussion Session, 4:30pm-6pm CDT in S406
Lead Author: David M. O’Malley, M.D., The Ohio State University College of Medicine
Location: Hall A
Abstract: 5520
Initial data from an investigator-sponsored trial through the National Comprehensive Cancer Network evaluating mirvetuximab in combination with gemcitabine in patients with FRa-positive recurrent epithelial ovarian, endometrial, or triple negative breast cancer will also be presented. Full dose mirvetuximab appears to combine well with gemcitabine, with a safety profile as expected for these agents and with encouraging anti-tumor activity seen in all three tumor types.
Title: “A phase 1 study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC)”
Day/Time: Saturday, June 1, 8:00am – 11:00am CDT and discussed at the Poster Discussion Session, 3:00pm-4:30pm CDT in E450
Lead Author: Mihaela C. Cristea, MD, City of Hope
Location: Hall A
Abstract: 3009
Additional information can be found at www.asco.org.
ABOUT FORWARD II
FORWARD II is a Phase 1b/2 study of mirvetuximab in combination with Avastin (bevacizumab), carboplatin or Keytruda (pembrolizumab) in patients with FRa-positive platinum-resistant or platinum-agnostic ovarian cancer, primary peritoneal, or fallopian tube tumors, as well as a triplet combination of mirvetuximab plus carboplatin and Avastin in patients with platinum-sensitive ovarian cancer.
ABOUT MIRVETUXIMAB SORAVTANSINE
Mirvetuximab soravtansine (IMGN853) is the first folate receptor alpha (FRa)-targeting ADC. It uses a humanized FRa-binding antibody to target the ADC specifically to FRa-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Avastin® is a registered trademark of Genentech, a member of the Roche Group."
* * $IMGN Video Chart 05-15-2019 * *
Link to Video - click here to watch the technical chart video
So many shorts here with the midpoint orders going on.
Seems the move is overdone, but the shorts want to get filled low.
Will see if they stuff it low again.
Crazy looking tape EOD yesterday..
Paint then Roll call????
05/09/19 17:41:52 3.20 0.00 0.00 1
05/09/19 17:41:37 3.20 0.00 0.00 1
05/09/19 17:41:22 3.20 0.00 0.00 1
05/09/19 17:41:07 3.20 0.00 0.00 1
05/09/19 17:23:52 3.05 0.00 0.00 1
05/09/19 17:23:37 3.05 0.00 0.00 1
05/09/19 17:23:22 3.16 0.00 0.00 1
05/09/19 17:23:07 3.16 0.00 0.00 1
05/09/19 17:19:52 3.20 0.00 0.00 0
05/09/19 17:19:37 3.20 0.00 0.00 0
05/09/19 17:19:22 3.20 0.00 0.00 0
05/09/19 17:19:07 3.20 0.00 0.00 0
05/09/19 16:41:52 3.20 0.00 0.00 8
05/09/19 16:41:37 3.20 0.00 0.00 8
05/09/19 16:41:22 3.20 0.00 0.00 8
05/09/19 16:41:07 3.20 0.00 0.00 8
05/09/19 16:37:48 3.20 2.96 3.20 0
05/09/19 16:31:23 3.20 3.16 3.22 6,300
05/09/19 16:26:43 3.20 3.16 3.22 0
05/09/19 16:26:43 3.20 2.96 3.22 1,800
05/09/19 16:23:48 3.20 2.96 3.22 0
05/09/19 16:18:52 3.20 0.00 0.00 0
05/09/19 16:18:37 3.20 0.00 0.00 0
05/09/19 16:18:22 3.20 0.00 0.00 0
05/09/19 16:18:07 3.20 0.00 0.00 0
05/09/19 16:10:26 3.20 2.96 3.20 0
05/09/19 16:09:03 3.20 3.15 3.20 0
05/09/19 16:07:49 3.20 3.16 3.22 0
05/09/19 16:07:13 3.20 3.15 3.22 2,400
05/09/19 16:06:29 3.20 3.15 3.22 900
05/09/19 16:06:26 3.20 3.15 3.22 1,200
05/09/19 16:06:24 3.20 3.15 3.22 1,000
05/09/19 16:05:07 3.14 3.15 3.22 0
05/09/19 16:03:30 3.14 3.14 3.22 0
05/09/19 16:02:49 3.14 3.14 3.21 0
05/09/19 16:00:20 3.14 3.13 3.21 100
05/09/19 16:00:13 3.20 3.13 3.21 200
05/09/19 16:00:11 3.14 3.13 3.21 100
05/09/19 16:00:03 3.20 3.13 3.21 600
05/09/19 16:00:03 3.20 3.13 3.21 19,400
05/09/19 16:00:03 3.20 3.13 3.21 2,300
05/09/19 16:00:03 3.20 3.13 3.21 800
05/09/19 16:00:03 3.20 3.13 3.21 100
05/09/19 16:00:03 3.20 3.13 3.21 6,600
05/09/19 16:00:03 3.20 3.13 3.21 0
* * $IMGN Video Chart 05-06-2019 * *
Link to Video - click here to watch the technical chart video
I believe that IMGN's movement since quarterly results were issued is purely based on anticipation that discussions with the FDA on a path to approval for IMGN853 will have a positive conclusion. Clearly the best course would be an agreement to submit a BLA this year based on the Phase 3 for the patient group that received the greatest benefit in the trial. As I see it, the worst case would require an additional trial that added more patients to the group receiving the greatest benefit, which would delay the approval by a couple years. Of course it's also possible that the Phase 2 Trials using drug combinations could result in an approval out of Phase 2.
Some of the combination trial data will be presented at ASCO. The Phase 3 Trial I believe will be discussed a few months later at ESMO. By the time of ESMO I think discussions with the FDA should have concluded, and the company can state what will come next. At the quarterly the company indicated that if discussions with the FDA go well, they'll submit a BLA for IMGN853 approval before the end of this year. If this comes to pass, I believe we'll see a ROW partnership and approval by the end of the first half of next year. I believe that highs not seen in a few years will be reached by the new year if a BLA is being filed, somewhere in the $20's is very possible.
Gary
* * $IMGN Video Chart 05-03-2019 * *
Link to Video - click here to watch the technical chart video
Novel financing - haven't noticed anything like this before:
News: $IMGN ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy FORWARD II Trial with Mirvetuximab Combinations Continues to Enr...
In case you are interested https://marketwirenews.com/news-releases/immunogen-reports-recent-progress-and-first-quarter-2019-financial-results-8108678.html
Atlas Financial Holdings. By removing the powerful broker tools from your trading weapons you will solve nothing. You will lose an edge, and they will always continue to manipulate and exploit number. Particularly market makers. Nothing you can do about that.
What is AFH???
I won't use broker software, too easy for them to track retail and exploit the numbers.
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1106
|
Created
|
02/12/02
|
Type
|
Free
|
Moderators |
http://www.immunogen.com/about-us
http://finance.yahoo.com/q/h?s=IMGN
Our mission is to be the leader in the application of monoclonal antibodies for the treatment of cancer. We aim to achieve this by exploiting our expertise and experience in the identification of potential biological targets for cancer treatments, the development and humanization of monoclonal antibodies, and the creation of potent cell-killing agents designed for delivery by antibodies. Our Targeted Antibody Payload(TAP) technology uses tumor-targeting antibodies to deliver a highly potent cell-killing agent specifically to cancer cells to kill these cells with minimal damage to healthy tissue.
We are committed to the highest standards of scientific excellence and integrity for the benefit of patients, the medical community, our partners, shareholders and employees.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |